FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2602847039> ?p ?o ?g. }

• W2602847039 endingPage "588" @default.
• W2602847039 startingPage "579" @default.
• W2602847039 abstract "Ceftazidime/avibactam comprises the broad-spectrum cephalosporin ceftazidime and the non-β-lactam β-lactamase inhibitor avibactam. This phase 3, randomised, double-blind study (NCT01726023) assessed the efficacy and safety of ceftazidime/avibactam plus metronidazole compared with meropenem in patients with complicated intra-abdominal infection (cIAI) in Asian countries. Subjects aged 18–90 years and hospitalised with cIAI requiring surgical intervention were randomised 1:1 to receive every 8 h either: ceftazidime/avibactam (2000/500 mg, 2-h infusion) followed by metronidazole (500 mg, 60-min infusion); or meropenem (1000 mg, 30-min infusion). Non-inferiority of ceftazidime/avibactam plus metronidazole to meropenem was concluded if the lower limit of the 95% confidence interval (CI) for the between-group difference in clinical cure rate was greater than −12.5% at the test-of-cure (TOC) visit (28–35 days after randomisation) in the clinically evaluable (CE) population. Safety was also evaluated. Of 441 subjects randomised, 432 received at least one dose of study medication (ceftazidime/avibactam plus metronidazole, n = 215; meropenem, n = 217). In the CE population at the TOC visit, non-inferiority of ceftazidime/avibactam plus metronidazole to meropenem was demonstrated, with clinical cure reported for 93.8% (166/177) and 94.0% (173/184) of subjects, respectively (between-group difference, −0.2, 95% CI −5.53 to 4.97). The clinical cure rate with ceftazidime/avibactam plus metronidazole was comparable in subjects with ceftazidime-non-susceptible and ceftazidime-susceptible isolates (95.7% vs. 92.1%, respectively). Adverse events were similar between the study groups. Ceftazidime/avibactam plus metronidazole was non-inferior to meropenem in the treatment of cIAIs in Asian populations and was effective against ceftazidime-non-susceptible pathogens. No new safety concerns were identified." @default.
• W2602847039 created "2017-04-07" @default.
• W2602847039 creator A5003337113 @default.
• W2602847039 creator A5005775087 @default.
• W2602847039 creator A5012661788 @default.
• W2602847039 creator A5020992600 @default.
• W2602847039 creator A5048456007 @default.
• W2602847039 creator A5049824246 @default.
• W2602847039 creator A5068290128 @default.
• W2602847039 creator A5071263465 @default.
• W2602847039 creator A5072249558 @default.
• W2602847039 creator A5088381316 @default.
• W2602847039 date "2017-05-01" @default.
• W2602847039 modified "2023-10-01" @default.
• W2602847039 title "A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia" @default.
• W2602847039 cites W1969500929 @default.
• W2602847039 cites W1986165865 @default.
• W2602847039 cites W2012223985 @default.
• W2602847039 cites W2017434072 @default.
• W2602847039 cites W2018229558 @default.
• W2602847039 cites W2022726996 @default.
• W2602847039 cites W2024275624 @default.
• W2602847039 cites W2026414172 @default.
• W2602847039 cites W2055457865 @default.
• W2602847039 cites W2091219913 @default.
• W2602847039 cites W2092279762 @default.
• W2602847039 cites W2114554564 @default.
• W2602847039 cites W2117154145 @default.
• W2602847039 cites W2117508830 @default.
• W2602847039 cites W2122633654 @default.
• W2602847039 cites W2125921606 @default.
• W2602847039 cites W2135825675 @default.
• W2602847039 cites W2137095286 @default.
• W2602847039 cites W2147796775 @default.
• W2602847039 cites W2149186506 @default.
• W2602847039 cites W2153512397 @default.
• W2602847039 cites W2159554754 @default.
• W2602847039 cites W2166358756 @default.
• W2602847039 cites W2171447404 @default.
• W2602847039 cites W2291267190 @default.
• W2602847039 cites W2294833633 @default.
• W2602847039 cites W2339819000 @default.
• W2602847039 cites W2437593726 @default.
• W2602847039 cites W2527930446 @default.
• W2602847039 doi "https://doi.org/10.1016/j.ijantimicag.2017.01.010" @default.
• W2602847039 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28363526" @default.
• W2602847039 hasPublicationYear "2017" @default.
• W2602847039 type Work @default.
• W2602847039 sameAs 2602847039 @default.
• W2602847039 citedByCount "91" @default.
• W2602847039 countsByYear W26028470392017 @default.
• W2602847039 countsByYear W26028470392018 @default.
• W2602847039 countsByYear W26028470392019 @default.
• W2602847039 countsByYear W26028470392020 @default.
• W2602847039 countsByYear W26028470392021 @default.
• W2602847039 countsByYear W26028470392022 @default.
• W2602847039 countsByYear W26028470392023 @default.
• W2602847039 crossrefType "journal-article" @default.
• W2602847039 hasAuthorship W2602847039A5003337113 @default.
• W2602847039 hasAuthorship W2602847039A5005775087 @default.
• W2602847039 hasAuthorship W2602847039A5012661788 @default.
• W2602847039 hasAuthorship W2602847039A5020992600 @default.
• W2602847039 hasAuthorship W2602847039A5048456007 @default.
• W2602847039 hasAuthorship W2602847039A5049824246 @default.
• W2602847039 hasAuthorship W2602847039A5068290128 @default.
• W2602847039 hasAuthorship W2602847039A5071263465 @default.
• W2602847039 hasAuthorship W2602847039A5072249558 @default.
• W2602847039 hasAuthorship W2602847039A5088381316 @default.
• W2602847039 hasBestOaLocation W26028470391 @default.
• W2602847039 hasConcept C126322002 @default.
• W2602847039 hasConcept C141071460 @default.
• W2602847039 hasConcept C197934379 @default.
• W2602847039 hasConcept C2775933652 @default.
• W2602847039 hasConcept C2776968632 @default.
• W2602847039 hasConcept C2777396551 @default.
• W2602847039 hasConcept C2777406300 @default.
• W2602847039 hasConcept C2777637488 @default.
• W2602847039 hasConcept C2779375183 @default.
• W2602847039 hasConcept C2908647359 @default.
• W2602847039 hasConcept C42219234 @default.
• W2602847039 hasConcept C501593827 @default.
• W2602847039 hasConcept C523546767 @default.
• W2602847039 hasConcept C54355233 @default.
• W2602847039 hasConcept C71924100 @default.
• W2602847039 hasConcept C86803240 @default.
• W2602847039 hasConcept C89423630 @default.
• W2602847039 hasConcept C94665300 @default.
• W2602847039 hasConcept C99454951 @default.
• W2602847039 hasConceptScore W2602847039C126322002 @default.
• W2602847039 hasConceptScore W2602847039C141071460 @default.
• W2602847039 hasConceptScore W2602847039C197934379 @default.
• W2602847039 hasConceptScore W2602847039C2775933652 @default.
• W2602847039 hasConceptScore W2602847039C2776968632 @default.
• W2602847039 hasConceptScore W2602847039C2777396551 @default.
• W2602847039 hasConceptScore W2602847039C2777406300 @default.
• W2602847039 hasConceptScore W2602847039C2777637488 @default.
• W2602847039 hasConceptScore W2602847039C2779375183 @default.
• W2602847039 hasConceptScore W2602847039C2908647359 @default.

• next